---
title: "TransThera Sciences Launches Discounted HK$290 Million H-Share Placement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282767094.md"
description: "TransThera Sciences (Nanjing), Inc. has announced a discounted placement of 5,085,000 new H shares at HK$57.03 each, representing about 1.27% of its existing share capital. The placement, which is expected to raise approximately HK$290 million, reflects an 18% discount to the last closing price. The shares will be issued to at least six professional or institutional investors under the company's existing mandate. Completion of the transaction is subject to conditions under the placing agreement."
datetime: "2026-04-14T22:39:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282767094.md)
  - [en](https://longbridge.com/en/news/282767094.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282767094.md)
---

# TransThera Sciences Launches Discounted HK$290 Million H-Share Placement

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An announcement from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available.

TransThera Sciences (Nanjing), Inc. has entered into a placing agreement with a sole placing agent to issue 5,085,000 new H shares at HK$57.03 each, representing about 1.27% of its existing share capital. The shares, to be placed with at least six professional or institutional investors, will be issued under the company’s existing general mandate without requiring additional shareholder approval.

The placing price reflects a discount of about 18% to the last closing price and roughly 19.2% to the five-day average, a common structure for accelerated fundraisings in Hong Kong. Assuming full placement, the transaction is expected to raise gross proceeds of approximately HK$290 million and net proceeds of about HK$282.15 million, with completion subject to conditions under the placing agreement, meaning the deal may or may not proceed.

**More about TransThera Sciences (Nanjing). Inc.**

TransThera Sciences (Nanjing), Inc. is a joint stock biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong. The company issues H shares on the Stock Exchange of Hong Kong and taps equity markets periodically to support its capital and operational needs.

**Average Trading Volume:** 2,494,355

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$20.84B

Find detailed analytics on 2617 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02617.HK](https://longbridge.com/en/quote/02617.HK.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)

## Related News & Research

- [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md)
- [ZAWYA: Emirates Drug Establishment approves first nasal epinephrine spray as alternative to injections for severe allergic reaction](https://longbridge.com/en/news/284603051.md)
- [Fagan Associates Inc. Acquires 24,910 Shares of Netflix, Inc. $NFLX](https://longbridge.com/en/news/284527634.md)
- [Wendell David Associates Inc. Has $11.92 Million Position in Church & Dwight Co., Inc. $CHD](https://longbridge.com/en/news/284774320.md)
- [CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026](https://longbridge.com/en/news/284213122.md)